AZTR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 15:59):

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases...

Stats
Today's Volume	11.71M
Average Volume	927 342
Market Cap	5.24M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $0 ) 2024-06-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.00200 (1.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Staskey Norm	Buy	47 600	Common Stock
2024-02-13	Whitfill Travis	Buy	15 000	Common Stock
2024-02-13	Staskey Norm	Buy	3 300	Common Stock
2024-02-13	Salva Francisco D.	Buy	333 300	Common Stock
2023-09-08	Staskey Norm	Buy	10 000	Stock Options (Right To Buy)

INSIDER POWER
44.35
Last 69 transactions
Buy: 15 407 806 \| Sell: 6 059 394

Volume Correlation

Long: -0.15 (neutral)

Short: -0.36 (neutral)

Signal:(41.701) Neutral

Azitra, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Azitra, Inc. Correlation - Currency/Commodity

-0.62
( weak negative )

-0.70
( moderate negative )

0.00
( neutral )

0.49
( neutral )

Azitra, Inc. Financials

Annual	2023
Revenue:	$686 000
Gross Profit:	$686 000 (100.00 %)
EPS:	$-1.630

FY	2023
Revenue:	$686 000
Gross Profit:	$686 000 (100.00 %)
EPS:	$-1.630

FY	2022
Revenue:	$284 000
Gross Profit:	$284 000 (100.00 %)
EPS:	$-0.880

Financial Reports:

No articles found.

Azitra, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Azitra, Inc.

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.